drugset
drugset / Trial / NCT03147976

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

NCT03147976 ↗

Phase 2 Withdrawn NantPharma, LLC
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2 study of AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations resulting in MET exon 14 skipping.

Timeline

Start
2018-05-02
Primary completion
2019-08-23
Completion
2019-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 337 Small molecule — —

Indications

cancer